<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00258284</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000445613</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-D-2615</secondary_id>
    <secondary_id>WSU-HIC-067903MP4F</secondary_id>
    <nct_id>NCT00258284</nct_id>
  </id_info>
  <brief_title>Capecitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer</brief_title>
  <official_title>Phase II Trial of Capecitabine (Xeloda) and Weekly Docetaxel (Taxotere) in Metastatic Androgen Independent Prostate Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as capecitabine and docetaxel, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving capecitabine together with docetaxel&#xD;
      works in treating patients with metastatic prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the response rate in patients with androgen-independent metastatic&#xD;
           adenocarcinoma of the prostate treated with capecitabine and docetaxel.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the progression-free survival, time to treatment failure, and overall survival&#xD;
           of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine&#xD;
      twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression&#xD;
      or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional&#xD;
      courses of therapy beyond CR&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 28 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate by RECIST criteria after every 2 courses</measure>
    <time_frame>at cycle 2 and every other cycle thereafter</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity at 30 days after last treatment</measure>
    <time_frame>Every week during treatment cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Every 2 cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>Every 2 cycles</time_frame>
    <description>From date of registration to date of progressive disease, or date patient is taken off study for any other reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Every 2 cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of treatment on biological correlates (thymidine phosphorylase, dihydropyrimidine dehydrogenase, thymidylate synthase)</measure>
    <time_frame>Every week during treatment cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel &amp; Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR</description>
    <arm_group_label>Docetaxel &amp; Capecitabine</arm_group_label>
    <other_name>Xeloda®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR</description>
    <arm_group_label>Docetaxel &amp; Capecitabine</arm_group_label>
    <other_name>Taxotere®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
               -  Androgen-independent disease&#xD;
&#xD;
          -  Progressive disease, as documented by ≥ 1 of the following criteria:&#xD;
&#xD;
               -  Rising prostate-specific antigen (PSA) despite androgen deprivation therapy and&#xD;
                  anti-androgen withdrawal&#xD;
&#xD;
                    -  Demonstrates a rising PSA trend with 2 successive elevations ≥ 1 week apart&#xD;
&#xD;
               -  Measurable disease progression&#xD;
&#xD;
               -  Nonmeasurable disease progression, defined as the following:&#xD;
&#xD;
                    -  PSA ≥ 5 ng/mL&#xD;
&#xD;
                    -  New areas of bone metastases on bone scan&#xD;
&#xD;
          -  Serum testosterone ≤ 0.5 ng/mL (castrate level)&#xD;
&#xD;
               -  Concurrent luteinizing hormone-releasing hormone agonist therapy required for&#xD;
                  medically castrated patients&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Zubrod 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/ mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  Transaminases meeting 1 of the following criteria:&#xD;
&#xD;
               -  AST and/or ALT ≤ 2.5 times upper limit of normal (ULN) if alkaline phosphatase&#xD;
                  (AP) normal&#xD;
&#xD;
               -  AP ≤ 4 times ULN if AST and/or ALT normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min OR&#xD;
&#xD;
          -  Creatinine ≤ 2 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No second- or third-degree heart block&#xD;
&#xD;
          -  No myocardial infarction within the past 3 months&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 6 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No other malignancy within the past 2 years except adequately treated skin cancer or&#xD;
             other cancer in complete remission&#xD;
&#xD;
          -  No history of severe hypersensitivity reaction to docetaxel or other drugs formulated&#xD;
             with polysorbate 80&#xD;
&#xD;
          -  No peripheral neuropathy ≥ grade 2&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy for metastatic disease&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior flutamide&#xD;
&#xD;
          -  More than 6 weeks since prior bicalutamide or nilutamide&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 28 days since prior investigational drugs for prostate cancer&#xD;
&#xD;
          -  No other concurrent anti-cancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulka N. Vaishampayan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>November 22, 2005</study_first_submitted>
  <study_first_submitted_qc>November 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2005</study_first_posted>
  <last_update_submitted>March 5, 2014</last_update_submitted>
  <last_update_submitted_qc>March 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barbara Ann Karmanos Cancer Institute</investigator_affiliation>
    <investigator_full_name>Ulka Vaishampayan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>adenocarcinoma of the prostate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

